Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.34 |
| ▸ | RXRA | P19793 | 2/20 | 0.33 |
| ▸ | PPARG | P37231 | 2/20 | 0.33 |
| ▸ | VCAM1 | P19320 | 3/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.31 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | XBP1 | P17861 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2160179 | 0.81 | SMN1; SMN2 (0.40) | NPSR1GPR55GAAL3MBTL1 | |
| SCHEMBL5983540 | 0.77 | VCAM1 (0.36) | VCAM1NPSR1GPR55L3MBTL1 | |
| SCHEMBL5984007 | 0.74 | VCAM1 (0.34) | VCAM1L3MBTL1 | |
| SCHEMBL5984640 | 0.73 | VCAM1 (0.32) | VCAM1NPSR1GPR55 | |
| SCHEMBL5984722 | 0.73 | VCAM1 (0.41) | VCAM1 | |
| SCHEMBL8144830 | 0.72 | PTGS1 (0.36) | ALOX5 | |
| SCHEMBL5985457 | 0.70 | — | — | |
| SCHEMBL8141137 | 0.69 | TDP1 (0.46) | GAAL3MBTL1 | |
| SCHEMBL5983556 | 0.68 | TUBB4A (0.39) | ALOX5GAA | |
| SCHEMBL5984662 | 0.67 | PTGS2 (0.37) | ALOX5ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040209958-A1 | Use of aryl nitrone compounds in methods for treating neuropathic pain | RENOVIS, INC. | 2004-10-21 | — | — | US | claimed |
| US-20020165274-A1 | Use of aryl nitrone compounds in methods for treating neuropathic pain | RENOVIS, INC. | 2002-11-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209958-A1 | Use of aryl nitrone compounds in methods for treating neuropathic pain | OPRL1, OPRK1, OPRD1 | ALOX5 400/4885RXRA 1423/4885PPARG 906/4885 |
| US-20020165274-A1 | Use of aryl nitrone compounds in methods for treating neuropathic pain | OPRL1, OPRD1, OPRK1 | ALOX5 363/4885RXRA 1527/4885PPARG 937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.